Ivermectine Pharmaki Generics (Ivermectin)

Ivermectin acts on a variety of helminthic and ectoparasitic diseases, reducing parasite burden and associated symptoms.

• Onchocerciasis: lowers microfilarial load and helps control disease progression.
• Strongyloidiasis: eradicates intestinal larvae and prevents disseminated infection.
• Lymphatic filariasis: reduces circulating microfilariae, aiding mass‑drug‑administration programs.
• Scabies: eliminates Sarcoptes mites, relieving itching and skin lesions.
• Pediculosis: kills head lice and nits, stopping infestation spread.

• Ivermectin binds selectively to glutamate‑gated chloride channels in the nerve and muscle cells of invertebrates. This binding increases chloride ion influx, causing hyperpolarization of the cell membrane, which leads to paralysis and death of the parasite while sparing mammalian cells that lack these channels.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: transient feeling of light‑headedness.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, usually self‑limiting.
• Abdominal pain: cramping or discomfort.
• Pruritus: mild skin itching.
• Headache: occasional tension‑type headache.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate care.
• Hepatic injury: elevated liver enzymes or jaundice.
• Neurologic toxicity: seizures or altered mental status.
• Anaphylaxis: rapid onset of allergic reaction.
• Vision changes: blurred vision or optic neuritis.
• Severe skin rash: extensive erythema or bullae.

Before prescribing ivermectin, clinicians should consider several safety factors.

• Assess liver function: evaluate hepatic status prior to initiation.
• Screen for Loa loa infection: avoid in patients with high microfilaremia due to risk of severe reactions.
• Use with caution in pregnancy: limited safety data, weigh benefits against potential risks.
• Monitor for drug interactions: especially with CYP3A4 or P‑gp inhibitors.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivermectin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase ivermectin plasma concentrations.
• P‑glycoprotein inhibitors (e.g., verapamil, quinidine): may raise systemic exposure.

Moderate Interactions (Monitor Closely)

• Warfarin: potential enhancement of anticoagulant effect, monitor INR.
• Macrolide antibiotics (e.g., erythromycin): may modestly increase ivermectin levels.
• Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce ivermectin efficacy by inducing metabolism.